Top > Search of International Patents > BLOOD BIOMARKER FOR USE IN EVALUATION OF EFFECT OF DRUG THERAPY ON KIDNEY CANCER

BLOOD BIOMARKER FOR USE IN EVALUATION OF EFFECT OF DRUG THERAPY ON KIDNEY CANCER

Foreign code F170009087
File No. (S2016-0050-N0)
Posted date May 30, 2017
Country WIPO
International application number 2016JP080084
International publication number WO 2017065127
Date of international filing Oct 11, 2016
Date of international publication Apr 20, 2017
Priority data
  • P2015-202614 (Oct 14, 2015) JP
Title BLOOD BIOMARKER FOR USE IN EVALUATION OF EFFECT OF DRUG THERAPY ON KIDNEY CANCER
Abstract Disclosed is a means whereby it becomes possible to evaluate the efficacy of a drug therapy agent on kidney cancer by a blood test in a simple manner. A method for assisting the evaluation of the effect of a drug therapy for the treatment of kidney cancer according to the present invention involves measuring the PARK7 level in a blood sample isolated from a kidney cancer patient who has been received the drug therapy for treating kidney cancer. An increased PARK7 level serves as a measure of a fact that the drug therapy is less effective. The efficacy of a candidate substance for a therapeutic drug for kidney cancer can be evaluated by employing a blood PARK7 level as a measure.
Outline of related art and contending technology BACKGROUND ART
Renal cancer in Japan per million people and the occurrence frequency is 10 and 7-8, has been increasing year by. Renal cancer therapy is the principle of surgical ablation, approximately 30% total renal cancer patients is called as a progressive transition the papermaking machine. Progressive cases it is difficult for the surgery, drug therapy or immunotherapy is applied.
Renal cancer patients currently available to the molecular target drug and drug therapy agent, inhibiting angiogenesis (TKI) other tyrosine kinase inhibitor, mTOR inhibitor is. Such drugs effectiveness of chemotherapy for renal cancer, a tumor was examined by CT image such as a scan has been determined by the reduction ratio. However, they are not reduced and may be hardly recognized, the determination itself is difficult to effect. For example, response rates of TKI (tumor reduction ratio) is, as the conventional anti-cancer agent of the present invention is not marked, or more reduced to allow the CT image 30% is about 10-30% cases. In addition, drug therapy is effective in patients, the reduced CT scan until the time when it usually several months. Therefore, at present, it is confirmed that the unequivocal progression in the image CT to continue the administration of the drug therapy.
TKI include hypertension, diarrhea, general malaise, such as a syndrome, which is different from the conventional anti-cancer agent of the various side effects, has been regarded as a problem. Drug therapy started treatment with a therapeutic effect at an earlier stage as long as the judgment, and the effect of the invalid epitamial not to continue the treatment is eliminated, leading to an improvement in QOL or the improvement of the prognosis of a patient. However, CT scan as described above in the lack of rapid effect determination problem. Moreover, CT scan is frequently that it is difficult from the problem of radiation exposure is, the timing of change of drug therapy may be delayed. Reflect the disease state of renal specific blood test method can be established (blood biomarkers), there is no problem of exposure and frequent inspection, CT scan or a facility not necessary timing is possible to determine the effect, that there is no blood biomarkers.
DJ-1 is, a novel cancer cells in a coordinated fashion as an oncogene ariga Cat 1997 et al. isolated a year. Then, this gene, the causative gene of familial Parkinson's disease in the year 2003 was isolated as PARK7, is now being referred to as PARK7/DJ1. PARK7/DJ1 is, for the protection of active oxygen and oxidative stress, transcriptional regulation, protease, and a report that the involved in the regulation mitochondrial function, non-small cell lung carcinomas also be pointed out that the correlation between the (non-patent document 1, 2). PARK7/DJ1 renal cancer (renal carcinoma) report, a report of 2009 year Sitaram et al. (Non-Patent Document 3) and 2013 (Non-Patent Document 4) reports Baumunk et al. is of the 2 cases.
In non-patent document 3, RT-PCR in DJ-1 PARK7 /, c-Myc and hTERT expression and analysis, the normal tissue expression of the DJ-1 PARK7/(n=49) (n=23) <<papillary renal cell carcinoma and renal clear cell renal cell carcinoma (RCC) (n=153) is highly expressed in the like have been reported, DJ-1, cMyc, hTERT expression and prognosis and no correlation is assumed.
In non-patent document 4, in the example RCC91 and the expression of the PDK-1 RT-PCR analysis of PARK7/DJ1 and, PARK7/DJ1 normal kidney tissue, expression was observed in both RCC, the difference in both, clinical, pathological correlation was not granted as is.
As described above, and the progression of renal PARK7 activity or expression in the tissue of the previously described correlation between the negative result is obtained in which, even in the renal blood PARK7 level correlation to the therapeutic effect of drug therapy, drug therapy for renal cancer PARK7 for determining the effect of the blood is useful as a biomarker, it is not known at all.
Scope of claims (In Japanese)[請求項1]
腎癌治療のための薬物療法を受けている腎癌患者から分離された血液試料中のPARK7レベルを測定することを含む、前記薬物療法の効果判定を補助する方法であって、PARK7レベルの上昇は、当該薬物療法が効果的ではないことの指標となる、方法。
[請求項2]
PARK7レベルが上昇したか否かが、前記患者の少なくとも前回測定値との比較により判断される、請求項1記載の方法。
[請求項3]
前記血液試料が血漿試料又は血清試料である、請求項1又は2記載の方法。
[請求項4]
腎癌薬物療法の効果判定血中バイオマーカーとしてのPARK7の使用。
[請求項5]
PARK7からなる、腎癌薬物療法の効果判定血中バイオマーカー。
[請求項6]
腎癌治療薬の候補物質の効果判定を補助する方法であって、腎癌を有する被検体から前記候補物質の投与前及び投与後に分離された血液試料中のPARK7レベルを測定することを含み、投与前の血液試料におけるPARK7レベルと比較して投与後の血液試料におけるPARK7レベルが低下している場合に、当該候補物質が腎癌治療に有効である可能性があると判定される、方法。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY
  • Inventor
  • NAKAIGAWA, Noboru
  • UENO, Daiki
  • YAO, Masahiro
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close